Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Intron in Heavily Treatment-experienced HIV
NCT00035360Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2002
- Primary completion
- Oct 2003
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
A Phase 3 trial of peginterferon alfa-2b in human immunodeficiency virus infection (HIV), sponsored by Merck & Co.. Started Mar 2002; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00035360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035360.